Perriman Damien Alan
An insider at 1 company in coverage, as reported on Form 4. SEC CIK 2096714. Latest Form 4 filed Oct 26, 2026.
Roles
As stated on the filings: the relationship to the company and any officer title.
| Company | Role | Transactions | First | Latest |
|---|---|---|---|---|
| Exozymes Inc.EXOZ | Chief Commercial Officer, Officer | 3 | 2026-10-09 | 2026-10-12 |
Transactions: 3
Every transaction reported, newest first, including grants, exercises and derivative securities. Purchases and sales (codes P and S) are open-market trades. The reported price is as stated on the form.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Company | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-12 | Exozymes Inc.Chief Commercial Officer, Officer | Sale | 3,729 | $5.2096 | $19.4k | Form 4 |
| 2026-10-09 | Exozymes Inc.Chief Commercial Officer, Officer | Option exerciseRestricted Stock Unit | 3,922 | $0.00 | $0 | Form 4 |
| 2026-10-09 | Exozymes Inc.Chief Commercial Officer, Officer | Option exercise | 3,922 | not reported | not reported | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 31, 2026, 06:27 ET. Listed shows no prices and gives no investment advice.